Clinical Trials Browser

pomalidomide × Plasma cell × 30 days × Clear all

NCT04973605 2026-04-16

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

Multiple Myeloma

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04108195 2026-04-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT04667663 2026-04-13

CPD-DARA

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-04-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 2 FDA

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06948084 2026-04-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04234022 2026-04-09

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Multiple Myeloma

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT04835129 2026-03-27

IMPEDE

Phase 2 Active not recruiting

Multiple Myeloma

NCT05020236 2026-03-27

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence